Community-Acquired Aspiration Pneumonia Antibiotic Regimens
Adult community-acquired aspiration pneumonia is treated with standard empiric community-acquired pneumonia (CAP) regimens. Additional anaerobic coverage should not be added routinely for suspected aspiration pneumonia unless lung abscess or empyema is suspected (conditional recommendation, very low quality of evidence). [1]
Medication Selection Algorithm
- Manage as CAP standard empiric therapy based on severity (outpatient vs inpatient) and risk for drug-resistant pathogens. [1]
- Do not routinely add anaerobic coverage for suspected aspiration pneumonia unless lung abscess or empyema is suspected. [1]
Outpatient Empiric Antibiotic Regimens
- Healthy outpatient adults without comorbidities or risk factors for antibiotic-resistant pathogens: [1]
- Amoxicillin 1 g PO three times daily, or [1]
- Doxycycline 100 mg PO twice daily, or [1]
-
A macrolide (azithromycin or clarithromycin) only in areas with pneumococcal resistance to macrolides <25%. [1]
-
Outpatient adults with comorbidities (chronic heart, chronic lung, chronic liver, or chronic renal disease; diabetes mellitus; alcoholism; malignancy; asplenia): [1]
- Combination therapy with amoxicillin/clavulanate (500/125 mg TID, or 875/125 mg BID, or 2,000/125 mg BID) or a cephalosporin (cefpodoxime 200 mg BID or cefuroxime 500 mg BID) PLUS a macrolide or doxycycline. [1]
- Acceptable partnered agents: azithromycin (500 mg day 1 then 250 mg daily), clarithromycin (500 mg BID), clarithromycin extended release (1,000 mg daily), or doxycycline (100 mg BID). [1]
Inpatient Empiric Antibiotic Regimens (Nonsevere)
Inpatient adults with nonsevere CAP without risk factors for MRSA or P. aeruginosa: [1]
- Combination therapy with a beta-lactam PLUS a macrolide (strong recommendation, high quality of evidence). [1]
- Beta-lactam options: ampicillin/sulbactam 1.5–3 g IV q6h, cefotaxime 1–2 g IV q8h, ceftriaxone 1–2 g IV daily, or ceftaroline 600 mg IV q12h. [1]
-
Macrolide options: azithromycin 500 mg IV daily or clarithromycin 500 mg IV BID. [1]
-
Or monotherapy with a respiratory fluoroquinolone (strong recommendation, high quality of evidence). [1]
-
Levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily. [1]
-
If macrolides and fluoroquinolones are contraindicated: beta-lactam PLUS doxycycline 100 mg PO/IV BID (conditional recommendation, low quality of evidence). [1]
Inpatient Empiric Antibiotic Regimens (Severe)
Inpatient adults with severe CAP without risk factors for MRSA or P. aeruginosa: [1]
- Beta-lactam PLUS a macrolide (strong recommendation, moderate quality of evidence). [1]
- Or beta-lactam PLUS a respiratory fluoroquinolone (strong recommendation, low quality of evidence). [1]
Anaerobic Coverage Indications and Guidance
- Anaerobic coverage is not routinely recommended for suspected aspiration pneumonia unless lung abscess or empyema is suspected (conditional recommendation, very low quality of evidence). [1]
Common Pitfalls to Avoid
- Routine addition of anaerobic coverage solely based on the label “aspiration pneumonia” is not recommended. [1]
Targets and Goals of Therapy
- Selection of empiric antibiotics should be aligned to standard CAP coverage recommendations and guided by CAP severity and drug-resistance risk stratification. [1]